First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease
ACS Chemical Neuroscience · 2024
DOI: 10.1021/acschemneuro.4c00061 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2024. Verfasst von Alan Santini und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso d'Augusto 237, 47921 Rimini, Italy. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Alzheimer Disease, Glycogen Synthase Kinase 3 beta. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: European Commission, Universit? degli Studi di Torino, Danmarks Frie Forskningsfond.
Themen: Demenz
Abstract (Originalsprache)
Despite recent FDA approvals, Alzheimer's disease (AD) still represents an unmet medical need. Among the different available therapeutic approaches, the development of multitarget molecules represents one of the most widely pursued. In this work, we present a second generation of dual ligands directed toward highly networked targets that are deeply involved in the development of the disease, namely, Histone Deacetylases (HDACs) and Glycogen Synthase Kinase 3β (GSK-3β). The synthesized compounds are highly potent GSK-3β, HDAC2, and HDAC6 inhibitors with IC50 values in the nanomolar range of concentrations. Among them, compound 4 inhibits histone H3 and tubulin acetylation at 0.1 μM concentration, blocks hyperphosphorylation of tau protein, and shows interesting immunomodulatory and neuroprotective properties. These features, together with its ability to cross the blood-brain barrier and its favorable physical-chemical properties, make compound 4 a promising hit for the development of innovative disease-modifying agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Corso d'Augusto 237, 47921 Rimini, Italy.
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Francesco Selmi 3, 40126 Bologna, Italy.
- Department of Biomedical and Neuromotor Science, Alma Mater Studiorum-University of Bologna, Piazza di Porta S. Donato, 2, 40126 Bologna, Italy.
- Department of Pharmacy, University of Pisa, Via Bonanno Pisano, 6, 56126 Pisa, Italy.
- Department of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.
- Center for Biopharmaceuticals and Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, DK-2100 Copenhagen, Denmark.
ORCID-Profile: Claudia Martini, Andrea Tarozzi, Francesca Spyrakis, Daniela Danková, Christian A Olsen, Andrea Milelli
Förderung
- European Commission
- Universit? degli Studi di Torino
- Danmarks Frie Forskningsfond
- Universit? di Bologna
- Ministero dell'Universit? e della Ricerca
- Universit? di Pisa
Zitieren
APA
Santini, A., Tassinari, E., Poeta, E., Loi, M., Ciani, E., Trazzi, S., Piccarducci, R., Daniele, S., Martini, C., Pagliarani, B., Tarozzi, A., Bersani, M., Spyrakis, F., Danková, D., Olsen, C. A., Soldati, R., Tumiatti, V., Montanari, S., De Simone, A., & Milelli, A. (2024). First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.4c00061
Vancouver
Santini A, Tassinari E, Poeta E, Loi M, Ciani E, Trazzi S, et al. First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease. ACS Chemical Neuroscience. 2024. doi:10.1021/acschemneuro.4c00061
BibTeX
@article{Santini2024,
author = {Santini, Alan and Tassinari, Elisa and Poeta, Eleonora and Loi, Manuela and Ciani, Elisabetta and Trazzi, Stefania and Piccarducci, Rebecca and Daniele, Simona and Martini, Claudia and Pagliarani, Barbara and Tarozzi, Andrea and Bersani, Matteo and Spyrakis, Francesca and Danková, Daniela and Olsen, Christian A and Soldati, Roberto and Tumiatti, Vincenzo and Montanari, Serena and De Simone, Angela and Milelli, Andrea},
title = {First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease},
journal = {ACS Chemical Neuroscience},
year = {2024},
doi = {10.1021/acschemneuro.4c00061}
}
EUVIMED